Navigation Links
Plicera in Medical Technology

Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease

Phase 2 Clinical Trials Initiated CRANBURY, N.J., March 21, 2007 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, announced today that it will present p...

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

...olly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, plicera and AT2220. Under the terms of the collaboration Shire will pay development and sales milestones up to a maximum of $390 million, and will also pay ti...

Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent

...trengthens our protection in the United States for plicera in Gaucher and is one example of our ongoing effor...armacological chaperone technology platform." plicera is currently being studied in an ongoing Phase 2 s...e third quarter of 2009. Amicus is developing plicera as part of a strategic collaboration with Shire Hu...

Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease

... medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. Forward-Looking Statements This press release contain...

Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009

...he dose and regimen for the Phase 3 studies. plicera (TM) (isofagomine tartrate) for the treatment of Gaucher Disease A Phase 2 clinical trial of plicera in Gaucher patients is ongoing. This 6 month study...er Shire HGT to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...

Amicus Therapeutics Announces Second Quarter 2008 Financial Results

... for the ongoing 6-month Phase 2 clinical trial of plicera in patients naive to ERT to include modified doses... The Company has modified its development plan for plicera to include a study of the pharmacokinetics of plicera in Gaucher patients. In addition, the company no l...

Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease

...Nashville, TN. The data demonstrate the ability of plicera to increase levels of the target enzyme in cells d...l data from both studies will also be presented. plicera is designed to selectively bind to and stabilize G... The following is a summary of the preclinical plicera data being presented at ACMG. - In vitro ex...
Plicera in Biological Technology

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

...rldwide will participate in this trial. plicera (TM) (afegostat tartrate) for the treatment of ...inical trial of the Company's investigational drug plicera is ongoing. This 6-month study is designed to eval..., Shire HGT, to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...

Publication of Shire plc's Annual Report 2008

...IGAL and AT2220, in markets outside the US. plicera (HGT-3410 for the treatment of Gaucher disease) plicera is an orally-administered, small molecule pharmaco...port the previously reported interim findings that plicera was generally safe and well tolerated at all doses...

Amicus Therapeutics Announces Change to Board of Directors

... medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. FOLD-G ...

Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results

... be available in the first quarter of 2009. plicera (TM) (isofagomine tartrate) for the treatment o...on executing its ongoing Phase 2 clinical trial of plicera in Gaucher disease. This 6-month study is designed..., Shire HGT, to prepare for Phase 3 development of plicera pending the results of the ongoing Phase 2 trial. ...

Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date

... medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. FOLD -G ...

Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors

...medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease. FOLD-G ...

Amicus Therapeutics Announces Third Quarter 2008 Financial Results

...ucher disease. As previously disclosed, a 6-month Phase 2 clinical trial of plicera in patients naive to ERT is ongoing and Amicus expects the results of this ...harmacological chaperone compounds for lysosomal storage disorders, Amigal, plicera and AT2220. In this collaboration, valued at up to $440 million including a...

Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.

...s Phase 2 trial support the previously reported interim findings that plicera was generally safe and well tolerated at all doses and increased target enzyme activity levels in a majority of patients. Shire has rights to plicera in markets outside the US. HGT-3510 - Pompe disease - In June 2008 Ami...

Amicus Therapeutics Announces First Quarter 2008 Financial Results

...macological chaperone Plicera. Results showed that plicera was generally safe and well tolerated at all doses...protocol for the 6-month Phase 2 clinical trial of plicera patients naive to ERT to include modified doses an...compounds for lysosomal storage disorders, Amigal, plicera and AT2220. In this collaboration valued at up to ...

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

...ine) METAZYM(TM) (arylsulfatase-A) MEZAVANT(R) (mesalazine) PENTASA (mesalamine) (trademark of Ferring) plicera (isofagomine tartrate) (trademark of Amicus) RAZADYNE (galantamine) (trademark of Johnson & Johnson ...
Other Tags
(Date:7/25/2014)... IL (PRWEB) July 25, 2014 Progress ... ushered in a new era of promising brain tumor ... Harvard Medical School, director of the Center for Neuro-Oncology, ... Association (ABTA) annual Patient and Family Conference in Chicago, ... how science and new technology are impacting the development ...
(Date:7/25/2014)... According to the new report "Sapphire ... and Geography - Analysis & Forecast to 2013 - ... to reach $3.01 Billion by 2020 at a CAGR ... devices is expected to reach $6.17 billion by 2020 ... analysis of application and geography. , Browse more than ...
(Date:7/25/2014)... Jose, CA (PRWEB) July 25, 2014 ... MaaS360 WorkPlace Partner Program . Splashtop Business and Splashtop ... Market, and will leverage the MaaS360 WorkPlace SDK ... data. , Splashtop Business and Splashtop Enterprise offer secure ... any device. High performance, ease of use, ...
(Date:7/25/2014)... Agoura Hills dentist , Dr. Amir ... Zoom Whitening is one of the most powerful whitening treatments ... professional. This light-assisted treatment uses a prescription-strength gel that can ... to break up stains that are in both the enamel ... soft drink and tobacco stains. , About Dr. Amir ...
(Date:7/25/2014)... IL (PRWEB) July 25, 2014 Garth Brooks ... performance at the Allstate Arena in Rosemont. Garth Brooks was ... time he released his first single in 1989. Since "Much Too ... flocked to the shows from the Tulsa, Okl. native and in ... wanted to see him back on a stage and in the ...
Breaking Medicine News(10 mins):Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 6Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 2Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 3Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 4Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 2Health News:Garth Brooks Chicago Tickets for Performance at Allstate Arena in Rosemont Go On Sale July 25th 3
(Date:7/24/2014)... in humans, affect the connections between nerve cells and ... an area of the brain that plays a significant ... The results of the study have been published in ... on the active communication between nerve cells, known as ... a dense network where they constantly relay signals to ...
(Date:7/24/2014)... in the United States, wildland managers often utilize the ... trees (ladder fuels). These cuttings and other post-logging ... danger in order to dispose of the material. To ... often cover all or part of the debris pile ... plastic, in order to keep water out. A recent ...
(Date:7/24/2014)... into the potato genes that best adapt to the ... rainfall and increased extremes of hot and cold temperatures.The ... order to create new potato varieties that will adapt ... to find out how the current potato varieties will ... and lower temperatures. , This research is part of ...
Breaking Biology News(10 mins):A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4Study gives new perspective on agricultural plastic, debris burning, and air quality 2Neiker-Tecnalia is researching the potato genes that best adapt to climate change 2
Other Contents